Finance

Beta
Lists
LUPIN:NSE
Lupin Ltd
₹2,275.00
-0.06%
(-1.40) 1D
May 29, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for LUPIN...
Open
₹2,289.00
High
₹2,301.40
Low
₹2,256.20
Mkt. cap
1.04T
Avg. vol.
1.25M
Volume
2.94M
P/E ratio
19.54
52-wk high
₹2,494.00
52-wk low
₹1,836.80
EPS
₹116.44
Shares outstanding
452.41M
No. of employees
24K
Open
₹2,289.00
High
₹2,301.40
Low
₹2,256.20
Mkt. cap
1.04T
Avg. vol.
1.25M
Volume
2.94M
P/E ratio
19.54
52-wk high
₹2,494.00
52-wk low
₹1,836.80
EPS
₹116.44
Shares outstanding
452.41M
No. of employees
24K
News stories
From sources across the web
Profile
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is primarily a manufacturer of generic drugs, covering therapeutic areas such as paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.The company operates in multiple international markets including the United States, Japan, Europe, and Australia.. Wikipedia
About Lupin Ltd
CEOVinita D. Gupta
Employees24K
Founded1968
HeadquartersMumbai, Maharashtra, India
SectorPharmaceutical industry
Websitelupin.com
Last report
May 8, 2026
Fiscal period
Q4 2026
EPS / Est. (INR)
₹34.75 / ₹27.93
+24.43%beat
Revenue / Est. (INR)
74.75B / 69.57B
+7.45%beat
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
62.68B
70.48B
71.68B
74.75B
Cost of goods sold
17.72B
18.25B
18.78B
18.52B
Cost of revenue
17.72B
18.25B
18.78B
18.52B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.83B
11.06B
11.43B
12.43B
Operating expense
30.40B
34.02B
33.93B
38.11B
Total operating expenses
48.12B
52.27B
52.71B
56.62B
Operating income
14.56B
18.21B
18.97B
18.12B
Other non operating income
790.40M
900.00M
1.15B
1.41B
EBT including unusual items
14.16B
20.07B
15.22B
19.28B
EBT excluding unusual items
15.29B
20.07B
19.49B
21.47B
Income tax expense
1.94B
5.22B
3.42B
4.59B
Effective tax rate
13.71%
26.02%
22.44%
23.82%
Other operating expenses
17.72B
19.80B
19.37B
22.09B
Net income
12.19B
14.78B
11.76B
14.60B
Net profit margin
19.45%
20.97%
16.40%
19.54%
Earnings per share
26.62
32.28
32.18
34.75
Interest and investment income
-
-
-
-
Interest expense
-917.60M
-1.08B
-1.15B
-1.20B
Net interest expenses
-917.60M
-1.08B
-1.15B
-1.20B
Depreciation and amortization charges
1.85B
3.17B
3.13B
3.59B
EBITDA
16.79B
21.29B
21.20B
21.28B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more